Previously defined markers for the identification of Tregs in MG patients, including CD25, FOXP3, and GITR [3, 4], are also increased during effector T cell activation; and a potent suppressive subset of Tregs cannot be characterized by these markers. This evidence concerns the gene TNFRSF18 and myasthenia gravis.